BRPI0818804A2 - Composto derivado de pirimidina, composição farmacêutica que o compreende e uso desse composto. - Google Patents

Composto derivado de pirimidina, composição farmacêutica que o compreende e uso desse composto.

Info

Publication number: BRPI0818804A2
Authority: BR; Brazil
Prior art keywords: compound; pharmaceutical composition; pyrimidine derivative; derivative compound; pyrimidine
Prior art date: 2007-11-01

Application number

Other languages

English (en)

Inventor

Martin Bolli

Claus Mueller

Boris Mathys

Olivier Nayler

Beat Steiner

Cyrille Lescop

Original Assignee

Actelion Pharmaceuticals Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-11-01

Filing date

2008-10-31

Publication date

2015-04-22

2008-10-31 Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd

2015-04-22 Publication of BRPI0818804A2 publication Critical patent/BRPI0818804A2/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Ophthalmology & Optometry (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Neurosurgery (AREA)
Obesity (AREA)
Transplantation (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Emergency Medicine (AREA)
Pain & Pain Management (AREA)
Oncology (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Otolaryngology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

BRPI0818804 2007-11-01 2008-10-31 Composto derivado de pirimidina, composição farmacêutica que o compreende e uso desse composto. BRPI0818804A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IB2007054437		2007-11-01
PCT/IB2008/054543 WO2009057079A2 (en)	2007-11-01	2008-10-31	Novel pyrimidine derivatives

Publications (1)

Publication Number	Publication Date
BRPI0818804A2 true BRPI0818804A2 (pt)	2015-04-22

Family

ID=40577704

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0818804 BRPI0818804A2 (pt)	2007-11-01	2008-10-31	Composto derivado de pirimidina, composição farmacêutica que o compreende e uso desse composto.

Country Status (18)

Country	Link
US (1)	US8299086B2 (pt)
EP (1)	EP2217594B1 (pt)
JP (1)	JP5517944B2 (pt)
KR (1)	KR20100092473A (pt)
CN (1)	CN101970430B (pt)
AR (1)	AR069146A1 (pt)
AU (1)	AU2008320374A1 (pt)
BR (1)	BRPI0818804A2 (pt)
CA (1)	CA2700917A1 (pt)
ES (1)	ES2449749T3 (pt)
IL (1)	IL205425A0 (pt)
MA (1)	MA31849B1 (pt)
MX (1)	MX2010004576A (pt)
NZ (1)	NZ585775A (pt)
RU (1)	RU2010121969A (pt)
TW (1)	TW200920746A (pt)
WO (1)	WO2009057079A2 (pt)
ZA (1)	ZA201003875B (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI392671B (zh) *	2006-09-07	2013-04-11	Actelion Pharmaceuticals Ltd	吡啶-４-基衍生物
ES2400163T3 (es) *	2006-09-08	2013-04-08	Actelion Pharmaceuticals Ltd.	Derivados de piridil-3-ilo como agentes de inmunomodulación
WO2008034142A2 (en)	2006-09-15	2008-03-20	Reviva Pharmaceuticals, Inc.	Synthesis, methods of using, and compositions of cycloalkylmethylamines
US8604244B2 (en)	2010-07-02	2013-12-10	Reviva Pharmaceuticals, Inc.	Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives
MX2009002915A (es) *	2006-09-21	2009-03-31	Actelion Pharmaceuticals Ltd	Derivados de fenilo y su uso como inmunomoduladores.
PT2125797E (pt) *	2007-03-16	2014-03-11	Actelion Pharmaceuticals Ltd	Derivados aminopiridina como agonistas do receptor s1p1/edg1
US8598208B2 (en) *	2007-08-17	2013-12-03	Actelion Pharmaceuticals Ltd.	Pyridine derivatives as S1P1/EDG1 receptor modulators
CN101965346A (zh) *	2008-03-06	2011-02-02	埃科特莱茵药品有限公司	新颖嘧啶-吡啶衍生物
JP5411877B2 (ja) *	2008-03-06	2014-02-12	アクテリオンファーマシューティカルズリミテッド	ピリジン化合物
AU2009220893A1 (en) *	2008-03-07	2009-09-11	Actelion Pharmaceuticals Ltd	Novel aminomethyl benzene derivatives
HRP20130641T1 (en) *	2008-03-07	2013-08-31	Actelion Pharmaceuticals Ltd.	Pyridin-2-yl derivatives as immunomodulating agents
ES2405054T3 (es)	2009-01-23	2013-05-30	Bristol-Myers Squibb Company	Derivados de pirazol-1,2,4-oxadiazol como agonistas de esfingosina-1-fosfato
EP2389377B1 (en)	2009-01-23	2014-07-16	Bristol-Myers Squibb Company	Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases
JP2012515787A (ja)	2009-01-23	2012-07-12	ブリストル−マイヤーズスクイブカンパニー	自己免疫疾患および炎症性疾患の処置におけるｓ１ｐアゴニストとしての置換オキサジアゾール誘導体
CN102471328B (zh)	2009-07-16	2015-04-01	埃科特莱茵药品有限公司	吡啶-4-基衍生物
US8399451B2 (en) *	2009-08-07	2013-03-19	Bristol-Myers Squibb Company	Heterocyclic compounds
JP5728487B2 (ja)	2009-10-29	2015-06-03	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	三環式ヘテロ環化合物
WO2011133734A1 (en)	2010-04-23	2011-10-27	Bristol-Myers Squibb Company	4 - (5 - isoxazolyl or 5 - pyrrazolyl -1,2,4- oxadiazol - 3 - yl) -mandelic acid amides as sphingosin- 1 - phosphate 1 rreceptor agonists
JP5788507B2 (ja)	2010-07-20	2015-09-30	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	置換３−フェニル−１，２，４−オキサジアゾール化合物
EP2619190B1 (en)	2010-09-24	2015-08-12	Bristol-Myers Squibb Company	Substituted oxadiazole compounds and their use as s1p1 agonists
WO2012061459A1 (en)	2010-11-03	2012-05-10	Bristol-Myers Squibb Company	Heterocyclic compounds as s1p1 agonists for the treatment of autoimmune and vascular diseases
HRP20150919T1 (hr)	2011-01-19	2015-09-25	Actelion Pharmaceuticals Ltd.	Derivati 2-metoksi-piridin-4-ila
RU2642074C2 (ru)	2011-12-30	2018-01-24	Ревива Фармасьютикалс, Инк.	Композиции, синтез и способы применения производных фенилциклоалкилметиламина
TWI613182B (zh)	2013-02-21	2018-02-01	必治妥美雅史谷比公司	雙環化合物
SG11201507227UA (en)	2013-03-15	2015-10-29	Actelion Pharmaceuticals Ltd	Pyridin-4-yl derivatives
TWI689487B (zh)	2014-08-20	2020-04-01	美商必治妥美雅史谷比公司	經取代雙環化合物
BR112017024785B1 (pt)	2015-05-20	2022-05-17	Idorsia Pharmaceuticals Ltd	Forma cristalina do composto (s)-3-{4-[5-(2-ciclopentil-6-metoxi-piridin-4-il)-[1,2,4] oxadiazol-3- il]-2-etil-6-metilfenoxi}-propano-1,2-diol, composição farmacêutica, e, uso
WO2017004609A1 (en) *	2015-07-02	2017-01-05	Exelixis, Inc.	Thiadiazole modulators of s1p and methods of making and using
ES2859478T3 (es)	2016-09-02	2021-10-04	Bristol Myers Squibb Co	Compuestos heterocíclicos tricíclicos sustituidos
WO2019032631A1 (en)	2017-08-09	2019-02-14	Bristol-Myers Squibb Company	Oxime ether compounds
US11046646B2 (en)	2017-08-09	2021-06-29	Bristol-Myers Squibb Company	Alkylphenyl compounds
WO2025230998A1 (en) *	2024-04-30	2025-11-06	University Of Massachusetts	Tec kinase agonists and their use in enhancing lymphocyte activation

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU7686891A (en)	1990-04-05	1991-10-30	American National Red Cross, The	A protein family related to immediate-early protein expressed by human endothelial cells during differentiation
WO1999046277A1 (en)	1998-03-09	1999-09-16	Smithkline Beecham Corporation	HUMAN EDG-1c POLYNUCLEOTIDES AND POLYPEPTIDES AND METHODS OF USE
NZ517221A (en)	1999-08-19	2004-01-30	Nps Pharma Inc	Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
US6559140B2 (en) *	2000-03-09	2003-05-06	Abbott Laboratories	Cyclic and bicyclic diamino histamine-3 receptor antagonists
IL160327A0 (en) *	2001-08-13	2004-07-25	Janssen Pharmaceutica Nv	2,4,5-trisubstituted thiazolyl derivatives and their antiinflammatory activity
ATE448193T1 (de)	2002-01-18	2009-11-15	Merck & Co Inc	ßN-(BENZYL)AMINOALKYL CARBOXYLATE, PHOSPHINATE, PHOSPHONATE UND TETRAZOLE ALS EDG REZEPTORAGONISTENß
US7479504B2 (en)	2002-01-18	2009-01-20	Merck & Co., Inc.	Edg receptor agonists
CA2491895C (en) *	2002-07-09	2011-01-18	Vertex Pharmaceuticals Incorporated	Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
WO2004035538A1 (en)	2002-10-15	2004-04-29	Merck & Co., Inc.	Process for making azetidine-3-carboxylic acid
US20060252741A1 (en) *	2003-05-15	2006-11-09	Colandrea Vincent J	3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists
CN1859908A (zh) *	2003-10-01	2006-11-08	默克公司	作为s1p受体激动剂的3,5－芳基、杂芳基或环烷基取代的－1,2,4－噁二唑类化合物
US7605171B2 (en)	2003-12-17	2009-10-20	Merck & Co., Inc.	(3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists
BRPI0511676A (pt)	2004-05-29	2008-01-08	7Tm Pharma As	uso medicinal de ligandos receptores
AU2005299851B2 (en)	2004-10-22	2011-03-17	Merck Sharp & Dohme Corp.	2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as S1P receptor agonists
US7786132B2 (en) *	2004-12-17	2010-08-31	Amgen Inc.	Aminopyrimidine compounds and methods of use
BRPI0612028A2 (pt)	2005-06-08	2010-10-13	Novartis Ag	oxadiazóis ou isodiazóis policìclicos e uso dos mesmos como ligantes de receptor s1p
EP1896011A1 (en)	2005-06-28	2008-03-12	AstraZeneca AB	New use
TWI404706B (zh) *	2006-01-11	2013-08-11	Actelion Pharmaceuticals Ltd	新穎噻吩衍生物
GB0601744D0 (en)	2006-01-27	2006-03-08	Novartis Ag	Organic compounds
BRPI0707957A2 (pt)	2006-02-21	2011-05-17	Univ Virginia Patent Found	composto, e, método para prevenção ou tratamento de uma condição ou sintoma patológico em um mamìfero
TWI392671B (zh)	2006-09-07	2013-04-11	Actelion Pharmaceuticals Ltd	吡啶-４-基衍生物
ES2400163T3 (es)	2006-09-08	2013-04-08	Actelion Pharmaceuticals Ltd.	Derivados de piridil-3-ilo como agentes de inmunomodulación
MX2009002915A (es)	2006-09-21	2009-03-31	Actelion Pharmaceuticals Ltd	Derivados de fenilo y su uso como inmunomoduladores.
SG177221A1 (en)	2006-12-15	2012-01-30	Abbott Lab	Novel oxadiazole compounds
WO2008091967A1 (en)	2007-01-26	2008-07-31	Smithkline Beecham Corporation	Chemical compounds
PT2125797E (pt)	2007-03-16	2014-03-11	Actelion Pharmaceuticals Ltd	Derivados aminopiridina como agonistas do receptor s1p1/edg1
JP5411877B2 (ja)	2008-03-06	2014-02-12	アクテリオンファーマシューティカルズリミテッド	ピリジン化合物
HRP20130641T1 (en)	2008-03-07	2013-08-31	Actelion Pharmaceuticals Ltd.	Pyridin-2-yl derivatives as immunomodulating agents
AU2009220893A1 (en)	2008-03-07	2009-09-11	Actelion Pharmaceuticals Ltd	Novel aminomethyl benzene derivatives
SI2291080T1 (sl)	2008-05-14	2015-11-30	The Scripps Research Institute	Novi modulatorji sfingosinskih fosfatnih receptorjev
CN102471328B (zh)	2009-07-16	2015-04-01	埃科特莱茵药品有限公司	吡啶-4-基衍生物

2008
- 2008-10-31 RU RU2010121969/04A patent/RU2010121969A/ru not_active Application Discontinuation
- 2008-10-31 MX MX2010004576A patent/MX2010004576A/es not_active Application Discontinuation
- 2008-10-31 KR KR1020107012070A patent/KR20100092473A/ko not_active Withdrawn
- 2008-10-31 TW TW097142254A patent/TW200920746A/zh unknown
- 2008-10-31 US US12/738,110 patent/US8299086B2/en not_active Expired - Fee Related
- 2008-10-31 BR BRPI0818804 patent/BRPI0818804A2/pt not_active IP Right Cessation
- 2008-10-31 AR ARP080104783A patent/AR069146A1/es not_active Application Discontinuation
- 2008-10-31 ES ES08846160.3T patent/ES2449749T3/es active Active
- 2008-10-31 NZ NZ585775A patent/NZ585775A/en not_active IP Right Cessation
- 2008-10-31 WO PCT/IB2008/054543 patent/WO2009057079A2/en not_active Ceased
- 2008-10-31 CA CA2700917A patent/CA2700917A1/en not_active Abandoned
- 2008-10-31 EP EP08846160.3A patent/EP2217594B1/en not_active Not-in-force
- 2008-10-31 CN CN2008801140168A patent/CN101970430B/zh not_active Expired - Fee Related
- 2008-10-31 AU AU2008320374A patent/AU2008320374A1/en not_active Abandoned
- 2008-10-31 JP JP2010531628A patent/JP5517944B2/ja not_active Expired - Fee Related
2010
- 2010-04-29 IL IL205425A patent/IL205425A0/en unknown
- 2010-05-17 MA MA32838A patent/MA31849B1/fr unknown
- 2010-05-31 ZA ZA2010/03875A patent/ZA201003875B/en unknown

Also Published As

Publication number	Publication date
NZ585775A (en)	2011-12-22
CN101970430B (zh)	2013-05-08
ES2449749T3 (es)	2014-03-21
EP2217594A2 (en)	2010-08-18
US8299086B2 (en)	2012-10-30
CA2700917A1 (en)	2009-05-07
AR069146A1 (es)	2009-12-30
AU2008320374A1 (en)	2009-05-07
TW200920746A (en)	2009-05-16
EP2217594B1 (en)	2014-01-08
KR20100092473A (ko)	2010-08-20
IL205425A0 (en)	2010-12-30
RU2010121969A (ru)	2011-12-10
ZA201003875B (en)	2012-08-29
JP5517944B2 (ja)	2014-06-11
US20100234346A1 (en)	2010-09-16
JP2011502980A (ja)	2011-01-27
CN101970430A (zh)	2011-02-09
WO2009057079A2 (en)	2009-05-07
MX2010004576A (es)	2010-05-17
WO2009057079A3 (en)	2009-12-03
MA31849B1 (fr)	2010-11-01

Publication	Publication Date	Title
BRPI0818804A2 (pt)	2015-04-22	Composto derivado de pirimidina, composição farmacêutica que o compreende e uso desse composto.
BRPI0815190A2 (pt)	2015-03-31	Composto derivado de piridina, composição farmacêutica que o compreende e uso do mesmo
BRPI0814593A2 (pt)	2015-01-20	Composto, composição farmacêutica que o contém e uso do composto.
BRPI0815079A2 (pt)	2015-02-03	Composto dericado de 1,2-diamido-etileno, composição farmacêutica que contém e uso desse composto
BRPI0821004A2 (pt)	2015-06-16	Composto derivado de aminopirazol, composição farmacêutica que o contem e uso deste
BRPI0908208A2 (pt)	2015-08-25	Composto derivado de oxazolidinona, medicamento, composição farmacêutica que o contém e uso desse composto.
BRPI0716171A2 (pt)	2013-09-17	composto, composiÇço farmacÊutica e uso de um composto.
BRPI0815709A2 (pt)	2017-06-13	composro, composição farmacêutica, e, uso de um composto.
BRPI0614205A2 (pt)	2016-11-22	composto, composição farmacêutica, e, uso de composto
BRPI0815170A2 (pt)	2015-03-31	Composição farmacêutica que compreende um inibidor de sglt 2
BRPI0720124A2 (pt)	2014-03-04	Composições farmacêuticas e seus métodos de uso.
BRPI0618904A2 (pt)	2016-09-13	composto, composição farmacêutica, e, uso do composto
BRPI0810696A2 (pt)	2014-10-21	Composto, composição farmacêutica, e, uso de um composto
CL2007003226A1 (es)	2008-02-08	Compuestos derivados de piridinona; composicion farmaceutica; y uso para tratar el cancer.
BRPI0609802A2 (pt)	2017-05-02	composto, composição farmacêutica e uso de um composto
BRPI0809977A2 (pt)	2014-10-07	Uso de um composto, compostos e composição farmacêutica que o contém
CL2007002916A1 (es)	2008-04-18	Compuestos derivados de pirazoliltienopiridinas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en la inhibicion de escaras.
SMP200900058B (it)	2010-11-12	Composti e composizioni come inibitori di proteinachinasi.
SM201000108A (it)	2011-01-19	Composti e composizioni come inibitori di proteinachinasi.
BRPI0821115A2 (pt)	2015-06-16	Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto
CL2007002377A1 (es)	2008-04-04	Compuestos derivados de quinazolina; procedimiento de preparacion; composicion farmaceutica; y su uso como anticancerigeno.
BRPI0813341A2 (pt)	2014-12-23	" uso de compostos, composições curáveis, e, uso de composições curáveis ".
CL2007001630A1 (es)	2008-02-08	Compuestos derivados de pirrolidinamida; composicion farmaceutica; y uso para el tratamiento de la hepatitis c.
BRPI0917661A2 (pt)	2015-12-01	produto que contém macitentan, composição farmacêutica que o contém e uso de macitentan
BRPI0716698A2 (pt)	2014-02-25	Composto, composição farmacêutica e uso de um composto

Legal Events

Date	Code	Title	Description
2015-12-01	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.
2016-04-05	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.